Kampanjeplan Intensity Therapeutics, Inc.
Avansert tidsplan
Enkel graf
Om selskapet
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. Its lead product candidate includes INT230-6, a clinical trial for the treatment of refractory solid tumors and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. The company was incorporated in 2012 and is headquartered in Westport, Connecticut.
EBITDA |
-0.0057 |
EV/EBITDA |
0.6288 |
IPO date |
2023-06-30 |
ISIN |
US45828J1034 |
Industry |
Biotechnology |
P/BV |
5.61 |
Sector |
Health Care |
Валюта |
usd |
Валюта отчета |
usd |
Сайт |
https://intensitytherapeutics.com
|
Цена ао |
5.33 |
Число акций ао |
0.00862 млрд |
Prisendring per dag: |
+3.68% (1.9) |
Prisendring per uke: |
+4.79% (1.88) |
Prisendring per måned: |
-29.33% (2.7875) |
Prisendring over 3 måneder: |
-48.56% (3.83) |
Prisendring over seks måneder: |
-59.55% (4.87) |
Prisendring per år: |
-77.01% (8.57) |
Prisendring over 3 år: |
0% (1.97) |
Prisendring over 5 år: |
0% (1.97) |
Prisendring over 10 år: |
0% (1.97) |
Prisendring siden begynnelsen av året: |
-3.19% (2.035) |
|
Undervurdering
Navn |
Betydning |
Karakter |
P/S |
0 |
0 |
P/BV |
4.17 |
4 |
P/E |
0 |
0 |
EV/EBITDA |
-5.69 |
0 |
Total: |
|
2.75 |
|
Effektivitet
Navn |
Betydning |
Karakter |
ROA, % |
-60.93 |
0 |
ROE, % |
-80.06 |
0 |
Total: |
|
0 |
|
|
Utbytte
Navn |
Betydning |
Karakter |
Div yield, % |
0 |
0 |
DSI |
0 |
0 |
Total: |
|
0 |
|
Plikt
Navn |
Betydning |
Karakter |
Debt/EBITDA |
-0.0193 |
10 |
Total: |
|
9.6 |
|
Vekstimpuls
Navn |
Betydning |
Karakter |
Lønnsomhet Revenue, % |
0 |
0 |
Lønnsomhet Ebitda, % |
76.95 |
8 |
Lønnsomhet EPS, % |
311.52 |
10 |
Total: |
|
7.2 |
|
Veileder |
Stillingstittel |
Betaling |
Fødselsår |
Mr. Lewis H. Bender M.A., M.B.A., M.S. |
Founder, President, CEO & Chairman of the Board |
1.1M |
1959 (66 år) |
Mr. John Wesolowski CPA, M.B.A. |
Principal Accounting Officer & Controller |
272.37k |
1960 (65 år) |
Mr. James M. Ahlers |
Executive Vice President of Corporate Finance |
75.09k |
1964 (61 år) |
Mr. Brian Schwartz M.D. |
Executive Vice President of Clinical Development |
N/A |
|
Mr. Joseph Talamo CPA, M.B.A. |
Chief Financial Officer |
N/A |
1969 (56 år) |